Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $19.50: Risk below floor (2.3 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.67; Below-average business quality.
Arcutis Biotherapeutics is a commercial-stage biopharma company focused on dermatological diseases, with four FDA-approved ZORYVE products (roflumilast formulations) for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis launched 2022–2025. Revenue comes from U.S.... Read more
Sell if holding. Engine safety override at $19.50: Risk below floor (2.3 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.67; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Score 6.1/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Arcutis Biotherapeutics, Inc.
Latest news
- Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance — Yahoo Finance negative
- Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Wednesday - MarketBeat — MarketBeat neutral
- Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com — Investing.com negative
- Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $31,661 in stock - Investing.com UK — Investing.com UK negative
- Arcutis Biotherapeutics (ARQT) officer sells 684 shares to cover RSU taxes - Stock Titan — Stock Titan negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductZORYVE10-K Item 1A: 'Our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful commercialization of ZORYVE'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Volatile — 6.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.50: Risk below floor (2.3 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.67; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Prior stop was $18.72. Score 6.1/10, moderate confidence.
Take-profit target: $30.12 (+54.5% upside). Prior stop was $18.72. Stop-loss: $18.72.
Concentration risk — Product: ZORYVE; Risk below floor (2.3 < 3.0).
Arcutis Biotherapeutics, Inc. trades at a P/E of N/A (forward 17.3). TrendMatrix value score: 7.7/10. Verdict: Sell.
14 analysts cover ARQT with a consensus score of 4.1/5. Average price target: $35.
What does Arcutis Biotherapeutics, Inc. do?Arcutis Biotherapeutics is a commercial-stage biopharma company focused on dermatological diseases, with four...
Arcutis Biotherapeutics is a commercial-stage biopharma company focused on dermatological diseases, with four FDA-approved ZORYVE products (roflumilast formulations) for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis launched 2022–2025. Revenue comes from U.S. prescription drug sales of ZORYVE, supplemented by licensing agreements with Huadong (Greater China/Southeast Asia) and Sato (Japan).